Norrie Disease (Pseudoglioma) (NDP) Peptid
Kurzübersicht für Norrie Disease (Pseudoglioma) (NDP) Peptid (ABIN937500)
Target
Spezies
Quelle
Applikation
-
-
Protein-Typ
- Synthetic
-
Sequenz
- DPRRCMRHHY VDSISHPLYK CSSKMVLLAR CEGHCSQASR SEPLVSFSTV
-
Produktmerkmale
-
A synthetic peptide for use as a blocking control in assays to test for specificity of NDP antibody,
Alternative Names: NDP control peptide, NDP antibody Blocking Peptide, Anti-NDP Blocking Peptide, Norrie Disease Blocking Peptide, Pseudoglioma Blocking Peptide, EVR2 Blocking Peptide, FEVR Blocking Peptide, ND Blocking Peptide -
Aufreinigung
- Rabbit Anti-p44/42 MAP Kinase (Ab-202) Polyclonal Antibody is affinity-purified from rabbit antiserum by affinity chromatography using epitope-specific immunogen.
-
-
-
-
Applikationshinweise
- Optimal conditions should be determined by the investigator
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handhabung
- Avoid repeated freeze/thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20 °C long term.
-
-
- Norrie Disease (Pseudoglioma) (NDP)
-
Hintergrund
- NDP activates the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptor. NDP plays a central role in retinal vascularization by acting as a ligand for FZD4 that signals via stabilizing beta-catenin (CTNNB1) and activating LEF/TCF-mediated transcriptional programs. NDP acts in concert with TSPAN12 to activate FZD4 independently of the Wnt-dependent activation of FZD4, suggesting the existence of a Wnt-independent signaling that also promote accumulation the beta-catenin (CTNNB1).
-
Molekulargewicht
- 15 kDa
Target
-